Taro Pharmaceutical Industries (TARO)
(Delayed Data from NYSE)
$42.52 USD
+0.10 (0.24%)
Updated May 21, 2024 04:00 PM ET
After-Market: $42.60 +0.08 (0.19%) 5:52 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TARO 42.52 +0.10(0.24%)
Will TARO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TARO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARO
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
TARO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Other News for TARO
Taro Pharmaceutical Reports Strong Fiscal Year
Taro: Fiscal Q4 Earnings Snapshot
Taro Provides Results for Year Ended March 31, 2024
TARO Stock Earnings: Taro Pharmaceutical Indus Reported Results for Q4 2024
Taro Pharmaceutical GAAP EPS of $0.40 beats by $0.09, revenue of $164.94M beats by $8.88M